Business
Corvus Pharmaceuticals Presents Updated Clinical Data Supporting and Refining the Adenosine Gene Signature’s Ability to Identify Patients Likely to Respond to Treatment with Ciforadenant
Elucidation of CD68 as a Downstream Target of Adenosine Refines Adenosine Gene Signature into a Practical Pathology Test Provides Opportunity to Further
About this update from Corvus Pharmaceuticals, Inc.
[{"type":"text","content":"Elucidation of CD68 as a Downstream Target of Adenosine Refines Adenosine Gene Signature into a Practical Pathology Test Provides Opportunity to Further Enrich Patient Selection for Responders\n Data Includes Additional Patients with Advanced Refractory Renal Cell Cancer, Supporting Earlier Results Published in Cancer Discovery in January Data Presented at the ASCO20 Virtual Scientific Program BURLINGAME, Calif., May 29, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhance patient selection, announced updated results from its Phase 1b/2 clinical trial of ciforadenant, its adenosine A2A receptor antagonist, in patients with advanced refractory renal cell carcinoma (RCC). The new data supports and refines the utility of the Adenosine Gene Signature (AdenoSig), which was discovered by Corvus, as a predictive biomarker to identify RCC patients most likely to respond to treatment with ciforadenant. The discovery of the AdenoSig was described in a research article published in Cancer Discovery in January 2020. In the publication, for 30 patients with available tumor biopsies, AdenoSig positive patients had a 17% objective response rate (ORR) by RECIST criteria compared to 0% in AdenoSig negative patients. In the new data, which covers over 50 patients, the ORR remained 17% for the Adenosine Gene Signature and improved to 27% with the refined version of the test, which is based the measurement of CD68 positive myeloid cells, the downstream target of adenosine. “We are pleased that the utility of the Adenosine Gene Signature as a biomarker for ciforadenant treatment has been supported in a larger number of patients,” said Richard A. Miller, M.D., president and chief executive officer of Corvus. “Through our recent work, we refined the signature to a single, practical IHC test that can be performed in a routine pathology lab based on the enumeration of CD68 positive myeloid cells. The underlying research that elucidated this refinement also contributed to a better understanding of the role of adenosine and its action in tumors. I am proud of the scientific achievements of our team, which has brought us closer to providing a potential novel,...